Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosenblum, W. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosenblum, W. I.

Stroke, Vol 19, 888-891, Copyright © 1988 by American Heart Association


ARTICLES

In vivo evidence that an adenylate cyclase-cAMP system dilates cerebral arterioles in mice

WI Rosenblum
Department of Pathology (Neuropathology), Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.

Pial arterioles of living mice anesthetized with urethane were monitored by television microscopy. I tested the existence of an adenylate cyclase-cyclic adenosine monophosphate (cAMP) system for dilating the arterioles by topically applying the following drugs: cAMP (10(-3) M), its more potent analogue dibutyryl cAMP (10(-3) and 10(-4) M), and forskolin (10(-6) M). Forskolin activates endogenous adenylate cyclase, which leads to increases in endogenous cAMP. Each drug was applied for 30 seconds; all three produced dilation. I then applied either cAMP or forskolin in the presence or absence of 10(-4) M isobutylmethylxanthine (IMX), an inhibitor of endogenous phosphodiesterase, which destroys cAMP. The presence of IMX significantly potentiated the dilation produced by exogenous cAMP and forskolin. These data indicate that cerebral surface arterioles of mice respond to cAMP with dilation and contain the enzymes for producing and inactivating this dilator. The existence of an adenylate cyclase-cAMP dilating mechanism in pial arterioles does not rule out the simultaneous existence of other dilating mechanisms.


This article has been cited by other articles:


Home page
Anesth. Analg.Home page
M. Uchida, H. Iida, M. Iida, M. Kumazawa, K. Sumi, M. Takenaka, and S. Dohi
Both Milrinone and Colforsin Daropate Attenuate the Sustained Pial Arteriolar Constriction Seen After Unclamping of an Abdominal Aortic Cross-Clamp in Rabbits
Anesth. Analg., July 1, 2005; 101(1): 9 - 16.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. W. Hong, H. K. Shin, H. H. Kim, J. M. Choi, B. Y. Rhim, and W. S. Lee
Metabolism of cAMP to adenosine: role in vasodilation of rat pial artery in response to hypotension
Am J Physiol Heart Circ Physiol, February 1, 1999; 276(2): H376 - H382.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Taguchi, D. D. Heistad, T. Kitazono, and F. M. Faraci
Dilatation of Cerebral Arterioles in Response to Activation of Adenylate Cyclase Is Dependent on Activation of Ca2+-Dependent K+ Channels
Circ. Res., June 1, 1995; 76(6): 1057 - 1062.
[Abstract] [Full Text]